Leading the future of targeted therapies for the hardest to treat cancers

We are next-generation targeted oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.

We're advancing plixorafenib in the registration-intended global FORTE phase 2 clinical trial

Following strong preclinical and early clinical results, an active phase 2 study is currently underway to assess the efficacy and safety of our lead candidate plixorafenib for previously treated patients with advanced, unresectable solid tumors harboring BRAF alterations.

Plixorafenib is an Investigational Drug and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Join a growing leader in the biotech industry.